Targeted Anti-IL-5 Therapies and Future Therapeutics for Hypereosinophilic Syndrome and Rare Eosinophilic Conditions
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeted Anti-IL-5 Therapies and Future Therapeutics for Hypereosinophilic Syndrome and Rare Eosinophilic Conditions
Authors
Keywords
-
Journal
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-01-09
DOI
10.1007/s12016-019-08775-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Benralizumab for PDGFRA-Negative Hypereosinophilic Syndrome
- (2019) Fei Li Kuang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dexpramipexole as an Oral Steroid-sparing Agent in Hypereosinophilic Syndromes
- (2018) Sandhya R. Panch et al. BLOOD
- Sa1114 - Efficacy and Safety of Rpc4046, an Anti-Interleukin-13 Monoclonal Antibody, in Patients with Active Eosinophilic Esophagitis: Analysis of the Steroid-Refractory Subgroup from the Heroes Study
- (2018) Evan S. Dellon et al. GASTROENTEROLOGY
- Dexpramipexole: a new antieosinophil drug?
- (2018) Gerald J. Gleich BLOOD
- Consequences of long-term OCS therapy and its side effects in severe asthma in adults – A focused review of the impact data in the literature
- (2018) Timm Volmer et al. EUROPEAN RESPIRATORY JOURNAL
- Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis
- (2017) Michael E. Wechsler et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adding Azathioprine to Remission-Induction Glucocorticoids for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss), Microscopic Polyangiitis, or Polyarteritis Nodosa Without Poor Prognosis Factors
- (2017) Xavier Puéchal et al. Arthritis & Rheumatology
- Intravenous anti–IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis
- (2015) Marc E. Rothenberg et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Molecular phenotyping and biomarker development: are we on our way towards targeted therapy for severe asthma?
- (2015) Laura De Ferrari et al. Expert Review of Respiratory Medicine
- Biologic Therapies Targeting Eosinophils: Current Status and Future Prospects
- (2015) Fanny Legrand et al. Journal of Allergy and Clinical Immunology-In Practice
- Diagnosis and classification of eosinophilic granulomatosis with polyangiitis (formerly named Churg–Strauss syndrome)
- (2014) Luc Mouthon et al. JOURNAL OF AUTOIMMUNITY
- ACG Clinical Guideline: Evidenced Based Approach to the Diagnosis and Management of Esophageal Eosinophilia and Eosinophilic Esophagitis (EoE)
- (2013) Evan S Dellon et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Targeting Interleukin-5 in Refractory and Relapsing Churg–Strauss Syndrome
- (2013) Frank Moosig et al. ANNALS OF INTERNAL MEDICINE
- Anti–IL-5 therapy reduces mast cell and IL-9 cell numbers in pediatric patients with eosinophilic esophagitis
- (2013) Iris M. Otani et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia
- (2013) Michel Laviolette et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes
- (2012) Peter Valent et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes
- (2012) Florence E. Roufosse et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Benralizumab – a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity – a novel approach for the treatment of asthma
- (2011) Aasia Ghazi et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Mepolizumab in eosinophilic disorders
- (2011) J Pablo Abonia et al. Expert Review of Clinical Immunology
- An Antibody Against IL-5 Reduces Numbers of Esophageal Intraepithelial Eosinophils in Children With Eosinophilic Esophagitis
- (2011) Amal H. Assa'ad et al. GASTROENTEROLOGY
- Reslizumab in children and adolescents with eosinophilic esophagitis: Results of a double-blind, randomized, placebo-controlled trial
- (2011) Jonathan M. Spergel et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- The American College of Rheumatology 1990 criteria for the classification of churg-strauss syndrome (allergic granulomatosis and angiitis)
- (2010) Alfonse T. Masi et al. ARTHRITIS AND RHEUMATISM
- Sustained response to mepolizumab in refractory Churg-Strauss syndrome
- (2010) Jean-Emmanuel Kahn et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome
- (2010) Florence Roufosse et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome
- (2010) Sophia Kim et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Mepolizumab does not alter levels of eosinophils, T cells, and mast cells in the duodenal mucosa in eosinophilic esophagitis
- (2010) Sébastien Conus et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function
- (2010) Roland Kolbeck et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- T-helper Type 2–driven Inflammation Defines Major Subphenotypes of Asthma
- (2009) Prescott G. Woodruff et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial
- (2009) A Straumann et al. GUT
- Treatment of a Case of Pediatric Hypereosinophilic Syndrome with Anti-Interleukin-5
- (2009) Sam Mehr et al. JOURNAL OF PEDIATRICS
- Anti–IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels
- (2008) Miguel L. Stein et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab
- (2008) Marc E. Rothenberg et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started